Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Albert Bourla

Pfizer Exec Booed During White House Appearance as Trump Calls Pharma Head 'Great Businessman'

President Donald Trump's introduction of a Pfizer executive at the White House Wednesday was met with a roar of boos from the crowd.

Latin Times

Pfizer CEO Booed At White House Event

President Trump's praise of Pfizer CEO at Black History Month event sparks mixed audience reactions due to company's Covid-19 vaccine controversy.

Top News

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Robert F. Kennedy had dinner with Pfizer CEO as he prepares to become health secretary, report says

Pfizer CEO certain that Trump’s administration ‘will be very, very prudent with everything they try to do’

The Independent UK

This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.

For savvy investors, Pfizer could be an undervalued stock to buy here.

Barchart

Eighty years after thousands of Greek Jews were murdered, Thessaloniki’s Holocaust museum is finally set to open

Germany is among donors committing millions to the long-awaited project, to be completed in 2026, which will tell story of those who perished

The Guardian - UK

Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter

Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

Gold price hits fresh record high, as bitcoin also rallies – as it happened

Analysts say gold is benefited from safe-haven demand amid persistent geopolitical tensions, expectations of monetary policy easing, and mounting uncertainty surrounding the US presidential election.

The Guardian - UK

As activist Starboard engages constructively, here’s a potent prescription for Pfizer’s future success under Dr. Bourla’s watch

Pfizer is getting back on track—but an even more potent prescription for success could be in the cards for the pharmaceutical giant under.

Fortune

Should You Follow Activist Investors Into This High-Yield Dividend Stock?

This dividend stock is now on the radar of activist investors, with Starboard eyeing a possible management shakeup.

Barchart

Pfizer stock surges after activist takes $1 billion stake

The drugmaker has shed nearly $180 billion in market cap after struggling to chart a new course as the COVID-19 pandemic waned.

Fortune

Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

The Independent UK

EU Chief's Texts For Covid Vaccines Under Court Scrutiny

A Belgian court on Friday heard a lawsuit accusing European Commission chief Ursula von der Leyen of secretly negotiating Covid vaccine purchases via text message and arguing she should be barred from a second term.

International Business Times

2 Cheap Dividend Stocks to Buy This March and Hold for the Long Term

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Pfizer Shares Tumble On Disappointing 2024 Profit Outlook

Pfizer issued a disappointing 2024 forecast Wednesday, denting shares as the company navigates a profound plunge in sales tied to the Covid-19 pandemic.

International Business Times

Pfizer Expects To Complete Purchase Of Seagen On Thursday

Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles.

The Independent UK

Company bosses and workers grapple with the fallout of speaking up about the Israel-Hamas war

The fallout from the Israel-Hamas war has spilled into workplaces everywhere, with corporate leaders from the highest ranks of prominent companies weighing in with their views while workers complain their voices are not being heard

Fortune

Pfizer CEO Albert Bourla wants to tap 'Chinese science' as the drug company looks for a new target after COVID

Bourla hopes to bring the same speed in developing a COVID vaccine to discovering new cancer treatments.

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Pfizer and Moderna parent are investing $100M to find the next big drug

"What we are doing now, I don’t think anyone has done so far," Pfizer CEO Albert Bourla says.

StockNews.com

Buy, Sell, or Hold: Pfizer Inc. (PFE)

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

Fortune

300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill ban

Pfizer’s Albert Bourla is among the CEOs who signed a letter against suspending mifepristone, citing its impact on the FDA and the biotech industry.

Bangkok Post

Chinese Foreign Minister Qin Gang assures US business leaders of Beijing's support

China remains committed to a "healthy, stable and constructive" relationship with the US amid still "chilly" bilateral ties, Chinese Foreign Minister Qin Gang told visiting American business leaders on Saturday.

Tribune News Service

Pfizer to pay $43 billion for Seagen, set post-COVID course

Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.

Bangkok Post

Pfizer buys biotech firm Seagen for $43 billion

WASHINGTON - US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.

The Independent UK

Pfizer will spend $43 billion to acquire Seagen

Pfizer will spend about $43 billion to buy Seagen and broaden its reach into cancer treatments, the pharmaceutical giant said Monday

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.